Related Experiment Videos
[Development of specific immunotherapy for cancer]
S Fujimoto1, K Araki, S Hamasato
1Department of Immunology, Kochi Medical School, Nankoku, Japan.
Human Cell
|September 1, 1992
Summary
This study introduces an improved cancer immunotherapy using T-cell therapies. Removing specific immune cells enhances T-cell induction, leading to effective cancer treatment without side effects.
Area of Science:
- Immunology
- Oncology
- Cancer Immunotherapy
Background:
- Cytotoxic T-lymphocyte (CTL) therapy is a cancer-specific immunotherapy.
- Primary CTL therapy shows efficacy in advanced cancer patients.
Observation:
- In advanced cancer patients, an increased monocyte population in peripheral blood lymphocytes (PBL) inhibits CTL induction when the CD8+ T-cell/monocyte ratio is less than 1.
- These monocytes release suppressive factors, including TGF-beta, hindering CTL induction and proliferation.
Findings:
- Removing monocytes from PBL using a nylon wool column method enables CTL induction in advanced cancer patients.
- This enhanced CTL therapy demonstrated significant efficacy in various advanced cancer patients.
Implications:
- This approach offers a promising cancer-specific immunotherapy strategy.
- The method shows potential for treating advanced cancers with minimal side effects.